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Abstract
Background: Mutations in the ZNF750 promoter and coding regions have been previously associated with
Mendelian forms of psoriasis and psoriasiform dermatitis. ZNF750 encodes a putative zinc finger transcription factor
that is highly expressed in keratinocytes and represents a candidate psoriasis gene.
Methods: We examined whether ZNF750 variants were associated with psoriasis in a large case-control population.
We sequenced the promoter and exon regions of ZNF750 in 716 Caucasian psoriasis cases and 397 Caucasian
controls.
Results: We identified a total of 47 variants, including 38 rare variants of which 35 were novel. Association testing
identified two ZNF750 haplotypes associated with psoriasis (p < 0.05). We also identified an excess of rare promoter
and 5’untranslated region (UTR) variants in psoriasis cases compared to controls (p = 0.041), whereas there was no
significant difference in the number of rare coding and rare 3’ UTR variants. Using a promoter functional assay in
stimulated human primary keratinocytes, we showed that four ZNF750 promoter and 5’ UTR variants displayed a
35-55% reduction of ZNF750 promoter activity, consistent with the promoter activity reduction seen in a Mendelian
psoriasis family with a ZNF750 promoter variant. However, the rare promoter and 5’ UTR variants identified in this
study did not strictly segregate with the psoriasis phenotype within families.
Conclusions: Two haplotypes of ZNF750 and rare 5’ regulatory variants of ZNF750 were found to be associated
with psoriasis. These rare 5’ regulatory variants, though not causal, might serve as a genetic modifier of psoriasis.
Background
Psoriasis is a chronic, inflammatory disorder of the skin
affecting 2-4% of the Caucasian population [1]. Clini-
cally, psoriasis is characterized by red, scaly plaques
typically favoring the elbows, knees, scalp, umbilicus,
and gluteal cleft and may be associated with nail dystro-
phy and arthritis. Histologically, psoriasis is marked by
epidermal hyperplasia, dilated vasculature in the dermal
papillae, and the presence of T cell infiltrates. Genome-
wide association studies and other genetic investigations
of psoriasis have identified at least 18 common variants
affecting psoriasis susceptibility [2-9]. However, in
aggregate, these common variants only explain a fraction
of the heritability in psoriasis [10]. Therefore, the
missing heritability in psoriasis might be explained by
other types of variants not captured by the previous
genetic studies, such as rare variants with a low minor
allele frequency in the general population.
One candidate susceptibility gene for psoriasis is
ZNF750, a gene located at chromosome 17q25 within
the PSORS2 locus. ZNF750 has previously been reported
to be associated with autosomal dominant forms of
psoriasis or psoriasiform dermatitis in two separate,
multigenerational families. The first family was a five-
generation Jewish Israeli family of Moroccan descent in
which affected members displayed clinical features of
both psoriasis and seborrheic dermatitis [11]. The causa-
tive mutation was identified as a ZNF750 frameshift
mutation at residue 19 of this 723-residue protein,
resulting in a 44-residue truncated protein which abro-
gated the zinc finger binding domain. The second family
was a five-generation Chinese family with psoriasis [12].
Gene mapping and functional studies identified the
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variant in ZNF750 that resulted in 42% reduction in
promoter activity.
Since Mendelian-pattern psoriasis in these two large
families is associated with ZNF750,w es o u g h tt oe x a m -
ine whether variants in ZNF750 might influence the
development of psoriasis in a larger population. In this
study, we investigated whether variants within the
ZNF750 promoter, 5’ UTR, coding regions, and 3’ UTR
were associated with psoriasis in a Caucasian
population.
Methods
Patients
DNA samples from 716 unrelated Caucasian psoriasis
cases, 397 Caucasian healthy adult controls, and 20
additional family members were collected from the Uni-
versity of California, San Francisco and Washington
University, St. Louis. Cases were recruited from outpati-
ent dermatology clinics and the diagnosis of psoriasis
was confirmed by a board-certified dermatologist.
Healthy controls, recruited from the local community,
reported no history of autoimmune disease or cancer
according to a written screening questionnaire. All sub-
jects gave written informed consent for study participa-
tion in accordance with the institutional review board at
their respective institutions.
Sequencing
Each DNA sample was sequenced over 6 amplicons to
cover the promoter and 3 exons of ZNF750.P C Rw a s
performed using the following primer pairs, sequences
listed 5’ to 3’: amplicon 1 (531 bp, forward AATACTG
TGCCTCCCAGGGTAT, reverse GTACTTACCAGA
GGTGGGCAGTG); amplicon 2 (710 bp, forward TGT
CCTGACACCAAGACTGC, reverse CGACTGGAAC
AAATGCAGAA); amplicon 3 (698 bp, forward GGCAT
CACCCTGCAAGAG, reverse GGTTTAACCTGGAAG
GACTCG); amplicon 4 (755 bp, forward CAGGCCA
GAGTCTGCATTTT, reverse TGGCTGCCAGGTTTA
TCTCT); amplicon 5 (673 bp, forward CCCTCAAC
CTCTCCAAGAAA, reverse GTGGCCGTAGCTCTGTG
AAC); amplicon 6 (783 bp, forward CTAACGCCGGG
TTCACAC, reverse GCACCCGTTCACAGGTTAAT).
PCR was performed using 8 ng genomic DNA, 0.4 μM
each forward and reverse primer, 1x buffer, 4 mM
dNTPs, and 0.3U Qiagen (Valencia, CA USA) HotStar
Taq and 1x Q Solution in a 10 μL reaction. PCR was
cleaned up by incubation with 1x SAP PCR Clean-Up
Reagent (PerkinElmer Life Sciences, Inc. Waltham, MA
USA) at 37°C for one hour. Sequencing reactions con-
tained 2.5 μL of clean PCR product, 0.375 μMp r i m e r
and 8.3% Applied Biosystems (ABI; Foster City, CA
USA) BigDye Terminator v3.1 in a 12 μL reaction.
Excess dye terminator removal was performed with gen-
CLEAN (Genetix; New Milton, Hampshire, United
Kingdom) plates following manufacturer’s instructions
before sequencing on an ABI 3730xL DNA Analyzer.
Sequencing was performed in one direction except for
amplicon 6 in which the presence of multiple indels
required the use of bidirectional sequencing, using the
internal reverse primer AGCCTCTTGATGTTTG
TGTGTT and internal forward primer TGGTTGTAAA
AACACCTGAATGA. All rare promoter and 5’ UTR
variants were sequenced a second time in the forward
and reverse directions to confirm their accuracy.
Statistical Methods
Sequencing traces were analyzed with Sequencher (Gene
Codes; Ann Arbor, MI USA). Hardy-Weinberg equili-
brium p-values were calculated in Haploview to assess
sequencing quality and a p-value of 0.05 was used as the
significance threshold for exclusion. Individual poly-
morphisms were tested for association with psoriasis
using Fisher’s exact test implemented in PLINK. Haplo-
view was used to identify haplotypes using the confi-
dence intervals method and to calculate haplotype
associations using a chi-square test. Haploview was also
used to perform empirical p-value estimation, using
100,000 permuted experiments. False discovery rate
(FDR) q-values were calculated in R. A weighted sum
statistic was used to test functionally similar groups of
rare variants for association with psoriasis. This
approach of combining multiple independent signals has
been shown to be significantly more powerful than var-
iant-by-variant or other approaches for the analysis of
rare variants [13]. 10,000 permutations were performed
to determine significance for each group tested.
5’ Rapid Amplification of cDNA Ends (5’ RACE)
SMART RACE cDNA amplification kit (BD Biosciences;
Franklin Lakes, NJ USA) was used to perform 5’-RACE
of ZNF750 gene. RACE-ready cDNA was synthesized
according to the manufacturer’s instructions. RACE
PCR was performed with gene-specific primers that
were used for RT-PCR of ZNF750 (Exon 2, GGAACTC-
GATCCTGCTCTGA). RACE products were excised
from the agarose gel, purified, and cloned into pGEM-T
easy vector (Promega Corp; Madison, WI USA). Cloned
inserts were sequenced with the T7 and SP6 primers
and the DNA sequences obtained were compared to
published sequences.
Reporter Constructs for ZNF750 Promoter Assay
The ZNF750 reference sequence was taken from
National Center for Biotechnology Information, with
accession number NM_024702. Five candidate muta-
tions in the promoter and 5’ UTR region of ZNF750
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Four novel variants were identified in patients diagnosed
with psoriasis and one mutation, c.-625A>C was identi-
fied by Yang et al [12]. An 849 bp insert containing the
promoter and 5’ UTR (exon 1 portion) of ZNF750 was
amplified from human genomic DNA using the primers
5’-CGGCTAGCCAGCAAGCAAGCAGTTTTGGT-3’
(NheI)a n d5 ’-CCAAGCTTGGATGTGGCCGGT
CTTGGT-3’ (HindIII), and cloned into pGL3 Basic vec-
tor (Promega) using NheI and HindIII restriction
enzymes. QuikChange II XL Site-Directed Mutagenesis
Kit (Agilent Technologies) was used to create the 5 var-
iations of interest individually. All vectors were
sequenced to verify the location of the variation.
Transfection and Luciferase Assay
Primary keratinocytes were provided by Dr. Dennis Oh
and Dr. Susana Ortiz-Urda (University of California San
Francisco, San Francisco, CA). The cells were grown in
500 ml Medium 154CF and Human Keratinocyte
Growth Supplement (Invitrogen; Carlsbad, CA USA),
and 35 μMo fC a C l 2. A total of 10
5 cells were seeded in
each well of a 6-well plate and were transfected after 24
hours with 500 ng of each reporter construct along with
10 ng of pRL-TK vector (Promega) containing the
Renilla luciferase gene as an indicator for normalization
of transfection efficiency. Transfections were performed
using Lipofectamine™ LTX with PLUS™ Reagent (Invi-
trogen), according to the manufacturer’si n s t r u c t i o n s .
After 24 hours, the cells were stimulated with 250 ng
phorbol-12-myristate-13-acetate (PMA) for the PMA
positive set of experiments. Cells were incubated for an
additional 24 hours and then analyzed for luciferase
activity with the Dual-Luciferase
® Reporter Assay Sys-
tem (Promega) and Synergy 2 (BioTek; Winooski, VT
USA). Firefly luminescence was normalized to Renilla
luminescence and reported as relative luciferase units
compared to wild-type sequence. All experiments were
performed independently three times using primary ker-
atinocytes from a single donor.
Results
Identification of ZNF750 Variants in Cases and Controls
To determine whether ZNF750 is associated with psor-
iasis, we sequenced ZNF750 in 716 Caucasian psoriasis
cases and 397 Caucasian controls. We sequenced the
ZNF750 promoter region (defined as 400 bp upstream
of the transcription start site), 5’ UTR, coding regions
which include exons 2 and 3, and 3’ UTR. In total, we
identified 9 common variants (minor allele frequency
(MAF) ≥ 2% in the controls, Table 1) and 38 rare var-
iants (MAF < 2%, Table 2). One polymorphism, a novel
8 bp deletion at position 78381172 (hg18) in the 3’
UTR, was out of Hardy-Weinberg equilibrium and was
not included. All identified polymorphisms were suc-
cessfully genotyped in greater than 94% of samples and
the mean genotyping rate per variant was 97.3%. Nearly
all variants were single nucleotide variants (SNVs) with
the exception of two single base deletions, one located
in the 3’ UTR (rs71918228) and the other in the 3’
downstream region (rs35156590). All of the identified
common variants were present in dbSNP Build 133
whereas 35 of 38 (92%) of the rare variants were novel.
Association Testing of Identified Variants
To analyze the significance of the identified ZNF750
variations/mutations in psoriasis patients, we first tested
each variant alone using a Fisher’se x a c tt e s t .F o rt h e
common variants (Table 1), only rs35156590 in the
immediate 3’ downstream region showed a significant
association with psoriasis (p = 0.028, OR 0.81 [95% CI
0.68-0.98]). However, adjustment for multiple hypothesis
testing using empirical permutation testing of this SNP
yielded p = 0.17. When tested individually, none of the
rare variants (Table 2) achieved a significance associa-
tion with psoriasis (all p > 0.05).
Table 1 Common variants identified in ZNF750
Name Position Property (PolyPhen2 impact) Alleles F_case F_control Fisher P
rs3744165 78383731 Exon 2, 5’ UTR C/A 0.171 0.161 0.541
rs12450046 78383677 Exon 2, 5’ UTR C/T 0.186 0.172 0.478
rs8074277 78382917 Exon 2, M235V (benign) A/G 0.189 0.18 0.640
rs35653278 78382757 Exon 2, P288L (probably) C/T 0.092 0.09 0.937
rs34188981 78382558 Exon 2, T354T C/T 0.021 0.021 1.000
rs12948179 78381781 Exon 3, P566P T/C 0.393 0.42 0.233
rs12938126 78381754 Exon 3, A575A A/G 0.392 0.42 0.232
rs71918228 78381176-79 Exon 3, 3’ UTR CAAA/- 0.465 0.478 0.586
rs35156590 78380584 3’ Downstream -/T 0.369 0.418 0.028
Common variants are defined as those with minor allele frequency (MAF) ≥ 2% in controls. Position is on Chr17 (hg18). UTR, untranslated region. PolyPhen2
impact given as benign, possibly damaging, or probably damaging. Alleles are given as major/minor on the (-) strand. F_case, MAF in cases; F_control, MAF in
controls.
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types of ZNF750 were associated with psoriasis. Two
8-marker haplotypes were significantly associated with
psoriasis (Table 3), the risk haplotype CCACCCG(-)
(frequency = 0.019, p = 0.0011, OR 3.70 [1.45-9.46])
which includes the risk allele of rs35156590, and the
protective haplotype CCACCCGT (frequency = 0.374,
p = 0.0106, 0.79 [0.66-0.94]) which contains the non-
risk allele of rs35156590. Both of these haplotypes
remained significant after correction for multiple com-
parisons using empirical permutation testing (p =
0.0024 and p = 0.0311, respectively) as well as by
Table 2 Rare variants identified in ZNF750
Name Position Property (PolyPhen2 impact) Alleles F_case F_control Fisher P
Novel_1 (c.-597C>T) 78391506 Promoter C/T 0 of 1312 1 of 745 0.363
Novel_2 (c.-458G>A) 78391367 Promoter G/A 1 of 1309 0 of 746 1.000
Novel_3 (c.-261G>A) 78391170 Exon 1, 5’ UTR G/A 1 of 1309 0 of 746 1.000
Novel_4 (c.-233 C>T) 78391142 Exon 1, 5’ UTR C/T 4 of 1306 0 of 746 0.303
Novel_5 (c.-232G>A) 78391141 Exon 1, 5’ UTR G/A 1 of 1311 0 of 746 1.000
Novel_6 (c.-45G>C) 78383664 Exon 2, 5’ UTR G/C 1 of 1349 0 of 746 1.000
Novel_7 (c.-36A>G) 78383655 Exon 2, 5’ UTR A/G 1 of 1349 0 of 746 1.000
Novel_8 (c.-32G>A) 78383651 Exon 2, 5’ UTR G/A 1 of 1349 0 of 746 1.000
Novel_9 78383521 Exon 2, T33T T/C 1 of 1349 0 of 746 1.000
Novel_10 78383438 Exon 2, R61Q (possibly) G/A 2 of 1348 1 of 745 1.000
Novel_11 78383402 Exon 2, P73L (probably) C/T 0 of 1350 1 of 745 0.357
Novel_12 78383393 Exon 2, T76I (benign) C/T 0 of 1350 1 of 745 0.357
Novel_13 78383325 Exon 2, D99N (probably) G/A 1 of 1349 1 of 745 1.000
Novel_14 78383272 Exon 2, E116E G/A 1 of 1349 0 of 746 1.000
Novel_15 78383216 Exon 2, A135E (benign) C/A 0 of 1350 1 of 745 0.357
Novel_16 78383196 Exon 2, A142T (possibly) G/A 1 of 1349 0 of 746 1.000
Novel_17 78382899 Exon 2, E241Q (probably) G/C 1 of 1357 0 of 752 1.000
Novel_18 78382882 Exon 2, F246F T/C 0 of 1358 1 of 751 0.356
rs35283702 78382791 Exon 2, G277R (probably) G/A 15 of 1343 7 of 745 0.825
Novel_19 78382759 Exon 2, H287Q (possibly) C/G 1 of 1357 0 of 752 1.000
Novel_20 78382489 Exon 2, F377L (benign) C/G 0 of 1374 1 of 763 0.359
rs34687659 78382445 Exon 2, Q392R (possibly) A/G 0 of 1374 1 of 763 0.359
Novel_21 78382401 Exon 2, A407T (probably) G/A 1 of 1373 0 of 764 1.000
Novel_22 78382375 Exon 2, P415P G/A 2 of 1372 2 of 762 0.622
Novel_23 78382326 Exon 2, D432H (possibly) G/C 2 of 1372 0 of 764 0.540
Novel_24 78382188 Exon 2, V478I (benign) G/A 0 of 1374 1 of 763 0.359
Novel_25 78382160 Intron 2 C/A 1 of 1373 0 of 764 1.000
Novel_26 78382155 Intron 2 A/C 1 of 1373 0 of 764 1.000
Novel_27 78382047 Intron 2, 5 bp from exon 3 T/C 1 of 1373 0 of 764 1.000
rs35792712 78382015 Exon 3, P488P T/G 0 of 1374 1 of 763 0.359
Novel_28 78381714 Exon 3, G589R (benign) G/C 1 of 1365 0 of 766 1.000
Novel_29 78381508 Exon 3, A657A G/A 1 of 1365 0 of 766 1.000
Novel_30 78381034 Exon 3, 3’ UTR G/A 1 of 1357 0 of 756 1.000
Novel_31 78380851 Exon 3, 3’ UTR A/G 1 of 1365 2 of 752 0.290
Novel_32 78380743 Exon 3, 3’ UTR A/G 2 of 1364 0 of 754 0.541
Novel_33 78380697 Exon 3, 3’ UTR T/G 1 of 1365 0 of 754 1.000
Novel_34 78380590 3’ Downstream T/C 2 of 1318 1 of 751 1.000
Novel_35 78380548 3’ Downstream G/A 17 of 1305 9 of 743 1.000
Rare variants are defined as those with minor allele frequency (MAF) < 2% in controls. SNPs Novel_1 through Novel_8 are additionally named by the nucleotide
position relative to the translation start site with respect to the cDNA reference. Position is on Chr17 (hg18). UTR, untranslated region. PolyPhen2 impact given as
benign, possibly damaging, or probably damaging. Alleles are given as major/minor on the (-) strand. F_case, MAF in cases; F_control, MAF in controls.
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q = 0.037, respectively).
Due to the well-recognized difficulty in assessing the sig-
nificance of rare variants on a variant-by-variant basis due
to power limitations [14], we utilized a weighted sum sta-
tistic [13] to evaluate functional groups of rare variants for
psoriasis association. We tested the following rare variant
groups: 5’ regulatory variants (promoter and 5’ UTR), all
coding variants, non-synonymous variants, predicted dele-
terious non-synonymous variants, 3’ UTR variants, and all
rare variants. We found that only the 5’ regulatory variants
trended towards a significant association with psoriasis (10
variants in cases, 1 variant in controls, unadjusted p =
0.041, Bonferroni threshold p = 0.008, Table 4). The puta-
tive association of the rare 5’ regulatory variants with psor-
iasis was not secondary to their occurrence on a risk
haplotype background. Of the 10 patients with rare 5’ regu-
latory variants, only 1 patient was heterozygous for the risk
haplotype CCACCCG(-), while 7 patients were actually
heterozygous for the protective haplotype CCACCCGT.
Alternative splicing of ZNF750 mRNA
In order to characterize the ZNF750 promoter and tran-
scripts, the size of ZNF750 mRNA was verified using
two methods: reverse transcriptase PCR (RT-PCR) and
5’ Rapid Amplification of cDNA Ends (5’ RACE). Using
RT-PCR, the predicted cDNA segments were amplified
from mRNA of normal individual skin biopsies. Com-
parison of the cDNA sequences to NCBI and UCSC
databases indicated that there are no alternative splicing
variants. 5’ Rapid Amplification of cDNA Ends per-
formed for ZNF750 in primary keratinocytes produced
four 5’ R A C EP C Rp r o d u c t st h a tw e r ec l o n e da n d
sequenced (data not shown). Alignments of the
sequences of the 5’ RACE PCR products with human
genomic DNA and known mRNA sequences indicated
that only two of the four products were specific to
ZNF750. The short product represents the mRNA iso-
form A as in Refseq gi13375990; NM_024702.1. The
long product, previously demonstrated in cDNA from
tongue tumor tissue [GenBank:DA436414][15] repre-
sents the mRNA isoform B and includes an additional
500 bp of sequence upstream to exon 1 of mRNA iso-
form A (Figure 1). The expression levels of the 5’-
RACE isoforms were studied by RT-PCR with forward
primers specific to isoform A and isoform B, respec-
tively, and a reverse primer specific to exon 2. RT-PCR
analyses of several cell lines (including primary keratino-
cytes) showed that the most abundant variant of
ZNF750 transcript corresponds to isoform A. Analysis
of all 3 reading frames indicated that isoform A and B
encode an identical protein: the addition of 500 bp
upstream in isoform B compared to isoform A does not
result in a different protein. Further investigation of the
protein size using WesternB l o td e m o n s t r a t e dt h a t
ZNF750 codes for a single protein of 100 KDa (data not
shown). Our data indicate that mRNA isoform A of
ZNF750 is the predominant form of ZNF750 expressed
Table 3 Haplotype association testing between cases and controls
Haplotype Hap Freq F_case F_control P Value Emp P-Val Odds Ratio [95% CI]
CCACCCGT 0.374 0.354 0.41 0.0106 0.0311 0.79 [0.66-0.94]
CCACCTA(-) 0.246 0.253 0.234 0.3321 0.9359 -
ACACCTA(-) 0.137 0.138 0.136 0.9158 1.0000 -
CTGCCTA(-) 0.089 0.091 0.085 0.6426 0.9995 -
CTGTCTA(-) 0.089 0.091 0.086 0.7198 0.9997 -
ACACTTA(-) 0.02 0.02 0.02 0.9666 1.0000 -
CCACCCG(-) 0.019 0.026 0.006 0.0011 0.0024 3.70 [1.45-9.46]
The eight marker haplotype, as ordered in the table, consists of: rs3744165, rs12450046, rs8074277, rs35653278, rs34188981, rs12948179, rs12938126, rs35156590.
Hap Freq, overall haplotype frequency; F_case, haplotype frequency in cases; F_control, haplotype frequency in controls; Emp P-Val, empiric p-value calculated by
permutation testing.
Table 4 Groupwise association testing of ZNF750 functional groups with psoriasis
Rare Variant Group Total Variants, Cases (n = 716) Total Variants, Controls (n = 397) P-value, Weighted Sum Statistic
5’ Regulatory (Promoter + 5’ UTR) 10 1 0.041
All Coding 30 19 0.575
- Non-synonymous 25 15 0.560
- Predicted deleterious 24 11 0.314
3’ UTR 5 2 0.351
All Rare 67 32 0.192
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identified in this study lie within the promoter region
and 5’ UTR of isoform A.
Functional evaluation of ZNF750 5’ Regulatory Variants
To assess whether the ZNF750 5’ regulatory variants
affect ZNF750 expression levels, we conducted a promo-
ter function assay in human primary keratinocytes.
S e v e nr a r ev a r i a n t si nt h e5 ’ regulatory region of
ZNF750 were seen in the psoriasis cases and none of
these were present in the controls (Table 2). All of these
variants were singletons with the exception of c.-
233C>T, which was present in 4 unrelated psoriasis
cases. None of these were present in individuals of Eur-
opean descent in the 1000 genomes database. We con-
structed ZNF750 5’ regulatory region fragments with 4
of the variants cloned into individual luciferase reporter
assay constructs. The 4 selected variants are located in
either the ZNF750 promoter region (c.-458G>A) or
ZNF750 untranslated first exon (c.-261G>A, c.-233C>T,
c.-232G>A) (Figure 1). Each construct was transfected
into human primary keratinocytes which are known to
highly express ZNF750 [11]. As an external control, we
also tested the activity of the c.-625A>C variant which
was shown to reduce promoter activity in the Taiwanese
familial psoriasis study [12]. We found that the c.-
458G>A promoter variant and the c.-261G>A 5’ UTR
v a r i a n ts h o w e das i g n i f i c a n tr e d u c t i o no f3 5 %a n d5 4 %
in promoter activity, respectively (p < 0.001). Both c.-
233C>T and c.-232G>A in the 5’ UTR showed a non-
significant reduction of 13% in promoter activity (Figure
2A). Our external control, the c.-625A>C variant,
showed a similar significant reduction of 40% in
promoter activity as previously published [12]. Interest-
ingly, human primary keratinocytes that have been sti-
mulated with phorbol 12-myristate 13-acetate (PMA)
have about 10 fold higher ZNF750 promoter activity
than unstimulated keratinocytes. Therefore, we tested
the effects of the 4 variants on promoter activity after
stimulation of human primary keratinocytes with PMA.
We found that all 4 of the variants, as well as the exter-
nal control, showed a significant reduction in promoter
activity of 35-55% compared to the wild type promoter
(all p < 0.001, Figure 2B).
Clinical Phenotype of Psoriasis Patients with 5’ Regulatory
Variants
To assess whether psoriasis patients with 5’ regulatory
variants have a similar clinical phenotype, we clinically
characterized the psoriasis patients with the ZNF750 5’
variants (Table 5). Of the 7 affected patients with
detailed clinical information available, 5 reported invol-
vement of the scalp or inverse skin folds, and a negative
history of psoriatic arthritis, similar to the sebo-psoria-
sis, arthritis-negative phenotype previously described in
the Israeli-Moroccan family with ZNF750 mutation [11].
Discussion
T oo u rk n o w l e d g e ,t h i si st h ef i r s tl a r g er e s e q u e n c i n g
study of the ZNF750 gene in psoriasis. As ZNF750
resides in the PSORS2 region [16-19] and has been pre-
viously reported to cause familial psoriasis forms of
psoriasis [11,12], we were motivated to evaluate ZNF750
in a large cohort of cases and controls. We sequenced a
total of 1,113 individuals (716 Caucasian psoriasis cases
and 397 ethnically matched healthy controls) in the
2  3  1 
Isoform A  Isoform B  NLS ZNF 
c.-233C>T/ 
c.-232G>A 
5’ regulatory variations  Deleterious mutation 
c.-261G>A 
NLS 
c.-458G>A 
c.-625A>C 
Chr17q25 
56_57dupCC 
Figure 1 ZNF750 gene structure and variants. ZNF750 consists of 3 exons, with the translation start site within exon 2. Narrow boxes indicate
5’ and 3’ untranslated regions; wider boxes indicate translated regions. ZNF750 contains two nuclear localization sites (NLS) and a C2H2 zinc
finger domain (ZNF). Arrows depict the locations of a deleterious frameshift mutation seen in a Jewish Moroccan family (56_57dupCC), promoter
and 5’ UTR variations examined in this study (c.-625A>C, c.-458G>A, c.-261G>A, c.-233 C>T, c.-232G>A), and start sites of ZNF750 mRNA isoforms
A and B.
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47 polymorphisms, of which 35 were novel. According
to estimates of Ionita-Laza et al [20], our study captured
greater than 99% of the variants with frequency greater
than 0.001 in the CEPH population. However, for per-
spective, we would have needed to sequence 3,521 indi-
viduals to capture 100% of the variants with frequency
greater than 0.001.
We conducted an association analysis of our identified
variants and found no evidence that individual common
polymorphisms (MAF > 2%) were associated with dis-
ease. Similarly, imputation of HapMap3/1000 Genomes
SNPs using psoriasis GWAS data [7] in the interval 200
kb upstream to 200 kb downstream of ZNF750 did not
find any SNPs with association p-values less than 1.0 ×
10
-3 (data not shown), suggesting that no common
ZNF750 SNPs are causal for psoriasis. However, our
finding that two ZNF750 haplotypes were significantly
associated with psoriasis suggests the possibility that
other SNPs on 17q in LD with these haplotypes could
possibly be associated with psoriasis. We also detected
several rare, non-synonymous, potentially deleterious
(PolyPhen2) coding variants in ZNF750 that were only
present in cases and not in controls, including A142T,
E241Q, H287Q, and A407T (Table 2). However, given
that each of these variants was only detected in a single
A 
B 
Figure 2 Luciferase activity of ZNF750 regulatory region in human primary keratinocytes. Bar chart representing luciferase activity of pGL3
constructs containing ZNF750 promoter and 5’ UTR variants relative to wild type promoter (WT). Four variants (c.-458G>A, c.-261G>A, c.-233C>T,
c.-232G>A) were detected in psoriasis patients in this study, one variant (c.-625A>C) was detected in a psoriasis family in previous study, and a
pGL3 basic (empty vector) was used as a negative control. Constructs were co-transfected with Renilla luciferase into primary human
keratinocytes and then treated for 24 h with culture medium (A) or culture medium supplemented with 250 ng/ml PMA (B). After 48 h, cells
were assayed for luciferase activity. A reduction in luciferase activity is seen for all 4 promoter and 5’ UTR variants as well as the c.-625A>C
external control. The results represent the means ± SD of three independent experiments. *** p < 0.001 compared to WT by t-test.
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determine whether these variants were truly deleterious.
Therefore, in order to more rigorously evaluate the pos-
sible association of rare variants in ZNF750 with psoria-
sis, we used the weighted-sum approach of Madsen and
Browning [13] to evaluate functional groups of rare var-
iants for disease association. This method has been
found to be robust compared to other rare variant ana-
lysis approaches such as CAST, CMC, Variable Thresh-
old, and Li-Leal [13,21]. We found that variants in the
promoter or 5’ UTR of ZNF750 were enriched in the
cases compared to controls (10 variants vs 1 variant, p =
0.041). Interestingly, the 1 variant found in a control but
in none of the cases was c.-597C>T, which was pre-
viously reported to be present in 1 of 85 sporadic psor-
iasis patients screened and 0 of 188 normal controls
[12]. In the same study, the promoter variant c.-625A>C
was linked to a multigenerational Taiwanese psoriasis
family and was reported to reduce ZNF750 promoter
activity by 42% [12]. We therefore investigated the func-
tional impact of 4 of our identified 5’ regulatory variants
in a promoter activity assay. We found that all 4 var-
iants, as well as the c.-625A>C external control, dis-
played decreased promoter activity compared to the
wild-type promoter. The observed effect on ZNF750
promoter activity was more pronounced in the presence
of the stimulator PMA, suggesting that the biological
effects of these variants could be dependent on environ-
mental variables such as immune stimulation or
response to external cues.
We obtained DNA from the family members of 6 pro-
bands with the rare 5’ regulatory ZNF750 variants. In a
segregation analysis examining the transmission pattern
of the rare variants in these six families, we did not
identify a clear autosomal dominant pattern (data not
shown). Considered together with our functional data,
two interpretations could be considered. The first is that
certain 5’ regulatory variants in ZNF750 could serve as a
genetic modifier of the psoriasis phenotype or act as an
incremental risk modifier similar to the common sus-
ceptibility alleles previously identified [4-8]. It should be
noted that the HLA-Cw6 allele, which confers the stron-
gest known risk on psoriasis susceptibility, has a pene-
trance of only 10% [22]. The existence of rare variants
that influence psoriasis risk but which have moderate,
non-Mendelian effect sizes is certainly possible but diffi-
cult to prove. Alternatively, it is possible that there is no
true association of 5’ regulatory variants in ZNF750 with
psoriasis and that the nominal association observed is
the result of type I error. In this case, the functional
effects of these variants on ZNF750 promoter activity
demonstrated here may not translate into biological
relevance for psoriasis. However, of the 7 patients iden-
tified in this study with ZNF750 5’ regulatory variants
and for whom detailed clinical descriptions were avail-
able, 5 reported scalp psoriasis and 3 reported inverse
psoriasis (axillae, genitals), which is reminiscent of the
sebo-psoriasis phenotype in the previously reported
Morrocan family with a frame shift ZNF750 mutation
[11]. Variants in the promoter and 5’ UTR of ZNF750
which decrease ZNF750 expression might therefore be
associated with a seborrheic form of psoriasis.
ZNF750 encodes a 723 amino acid protein that con-
tains two nuclear localization sites (NLS), and two histi-
dines and two cysteines that might serve as zinc binding
domains. ZNF750 is a putative member of the C2H2
Table 5 Clinical characteristics of subjects with rare ZNF750 variants in the 5’ regulatory region
ZNF750
Variant
# Pso
Cases
Age: Study
Entry (Onset)
Gender PsA Family History of
Psoriasis
Description
c.-
458G>A
1 NA Female Yes Sister Confirmed psoriasis, no other information available
c.-
261G>A
1 57 (35) Male No Mother, brother,
daughter, niece, nephew
Confirmed psoriasis
c.-233C>T 4 41 (25) Female No Mother, sister Plaque and inverse psoriasis affecting scalp, trunk, extremities,
breast folds, axillae, and genitals.
32 (15) Female No Mother Plaque psoriasis with 10-20% BSA affecting scalp, trunk, arms, legs
34 (5) Male No Father, sister Guttate psoriasis affecting the scalp, trunk, and arms with 5-10%
BSA
54 (35) Female No Sister Plaque psoriasis affecting elbows, knees, and legs with 10-20% BSA
c.-
232G>A
1 43 (30) Male No Maternal cousin Moderate plaque and inverse psoriasis affecting scalp, elbows, legs,
axillae, genitals, and nails
c.-45G>C 1 30 (5) Female No Father Moderate guttate (originally plaque) and inverse psoriasis affecting
scalp, arms, legs, trunk, axillae, and genitals
c.-36A>G 1 40 (25) Female No Sister Moderate psoriasis affecting trunk, legs
c.-32G>A 1 65 (NA) Male No NA Confirmed psoriasis
All psoriasis cases were of Caucasian ethnicity. PsA, psoriatic arthritis diagnosed by rheumatologist; BSA, affected body surface area. NA, information not
available.
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Page 8 of 10subclass of zinc finger transcription factors. ZNF750 is
highly expressed in keratinocytes, which are the major
skin cell type affected both in seborrheic dermatitis and
in psoriasis. In addition, human primary keratinocytes
that have been differentiated with Ca
2+ have increased
ZNF750 promoter activity at levels similar to PMA sti-
mulated cells (unpublished data), suggesting ZNF750
may serve an important function in keratinocyte differ-
entiation or immune response in the skin. As keratino-
cytes in psoriasis or seborrheic dermatitis secrete factors
that recruit cells of the immune system and help main-
tain the inflammatory response [23,24], it is possible
that an insufficient level of ZNF750 could lead to a
downstream effect that fails to repress a stimulated
immune response in psoriasis or seborrheic dermatitis.
Conclusions
In summary, we have performed the first re-sequencing
study of the candidate psoriasis gene ZNF750 in a large
case-control population. Although no individual variants
were found to associate with psoriasis, two ZNF750 hap-
lotypes showed a significant association. We also
observed a nominal association between rare variants in
the 5’ regulatory region of ZNF750 and psoriasis. Collec-
tively, these rare 5’ regulatory variants were seen in 10
of 716 (1.4%) of the psoriasis population surveyed. Func-
tional assays demonstrated that 4 of these variants
decreased ZNF750 promoter activity in accordance with
previous reports in psoriasis [12] and psoriasiform der-
matitis [11]. We found that these variants did not segre-
gate with the psoriasis phenotype within families,
suggesting that they are modifier variants rather than
causal for psoriasis. Further studies are warranted to
determine whether these rare, non-coding variants could
play an influencing role in disease expression.
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